Bioventus Inc. Files 8-K on Officer/Director Changes
Ticker: BVS · Form: 8-K · Filed: Nov 17, 2025 · CIK: 1665988
Sentiment: neutral
Topics: officer-changes, director-changes, compensation
Related Tickers: BVS
TL;DR
Bioventus filed an 8-K for director/officer changes and compensation.
AI Summary
Bioventus Inc. filed an 8-K on November 17, 2025, reporting events as of November 14, 2025. The filing pertains to the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. Specific details regarding names, dollar amounts, and precise dates of these events are not provided in this excerpt.
Why It Matters
Changes in a company's board of directors or executive officers can signal shifts in strategy, governance, or operational focus.
Risk Assessment
Risk Level: medium — Changes in key personnel and executive compensation can indicate internal shifts that may impact future performance or strategy.
Key Players & Entities
- Bioventus Inc. (company) — Registrant
- November 14, 2025 (date) — Earliest event reported
- November 17, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- Durham, North Carolina (location) — Principal executive offices
FAQ
What specific events are detailed in the 8-K filing?
The 8-K filing pertains to the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements of certain officers.
What is the exact date of the earliest event reported in this filing?
The earliest event reported is dated November 14, 2025.
When was this 8-K form filed with the SEC?
The 8-K form was filed as of November 17, 2025.
What is the principal executive office address for Bioventus Inc.?
The principal executive offices are located at 4721 Emperor Boulevard, Suite 100, Durham, North Carolina 27703.
What is the SIC code for Bioventus Inc.?
The Standard Industrial Classification (SIC) code for Bioventus Inc. is 3841, which corresponds to SURGICAL & MEDICAL INSTRUMENTS & APPARATUS.
Filing Stats: 781 words · 3 min read · ~3 pages · Grade level 11 · Accepted 2025-11-17 17:04:41
Key Financial Figures
- $0.001 — hich registered Class A common Stock, $0.001 par value per share BVS The Nasdaq Glob
Filing Documents
- bvs-20251114.htm (8-K) — 29KB
- 0001665988-25-000032.txt ( ) — 178KB
- bvs-20251114.xsd (EX-101.SCH) — 2KB
- bvs-20251114_def.xml (EX-101.DEF) — 15KB
- bvs-20251114_lab.xml (EX-101.LAB) — 26KB
- bvs-20251114_pre.xml (EX-101.PRE) — 16KB
- bvs-20251114_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOVENTUS INC. Date: November 14, 2025 By: /s/ Anthony D'Adamio Anthony D'Adamio Senior Vice President and General Counsel